: It reduces "leaky gut" markers like Lipopolysaccharide-binding protein (LBP).
As an emerging technology, Ymeta faces several hurdles:
Consult with a to check for interactions.
in data models) to predict all-cause mortality and disease risk.
: Encourages the growth of bacteria associated with lean phenotypes and healthy glucose metabolism.